The Mexican Schedule to Conduct Allogeneic Stem Cell Transplantation Is Related to a Low Risk of Cytomegalovirus Reactivation and Disease

American Journal of Hematology

Volumn 75, Issue 4, 2004, Pages 200-204

  Ruiz Argüelles, Guillermo J ^a,b   Gómez Rangel, J David ^a   Ponce De León, Samuel ^c   González Déctor, Laura ^a,d   Reyes Núñez, Virginia ^b   Garcés Eisele, Javier ^b,d  

^a CENTRO DE HEMATOLOGÍA Y MEDICINA INTERNA DE PUEBLA   (Mexico)

^b Laboratorios Clinicos de Puebla   (Mexico)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^d UNIVERSIDAD DE LAS AMÉRICAS PUEBLA   (Mexico)

Author keywords

Allograft; Antigenemia; Cytomegalovirus; Non myeloablative; Reactivation

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYTOMEGALOVIRUS ANTIBODY; FLUDARABINE; IMMUNOGLOBULIN G ANTIBODY; MESSENGER RNA; THYMOCYTE ANTIBODY;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGRAFT; ARTICLE; CHILD; CLINICAL ARTICLE; CONDITIONING; CONTROLLED STUDY; COST CONTROL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REGIMEN; FEMALE; GRAFT VERSUS HOST REACTION; HEALTH CARE COST; HUMAN; HUMAN CELL; MALE; MEXICO; MORBIDITY; MORTALITY; ORGAN DONOR; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; VIRUS REACTIVATION;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, VIRAL; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; VIRUS ACTIVATION;

EID: 1842479436     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20026     Document Type: Article

References (30)

1. Georges G, Storb R. Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation. Int J Hematol 2003;77:3-14.
2. Djulbegovic B, Seidenfeld J, Bonnell C, Kumar A. Nonmyeloablative allogeneic stem-cell transplantation for hematologic malignancies: a systematic review. Cancer Control 2003;10:17-31.
3. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematological diseases. Blood 1998;91:756-763.
4. Giralt S, Estey E, Albitar M, van Besien K, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analogue-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531-4536.
5. Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-Argüelles A, González-Llano O, Cantú OG, Jaime-Pérez JC. Results of an outpatient-based stem cell allotransplant program using non-myeloablative conditioning regimens. Am J Hematol 2001;66:241-244.
6. Ruiz-Argüelles GJ, Gómez-Almaguer D, Ló pez-Martínez B, Cantú-Rodríguez OG, Jaime-Pérez JC, González-Llano O, Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. Haematologica 2002;87:894-896.
7. Ruiz-Argüelles GJ. Allogeneic stem cell transplantation using non-myeloablative conditioning regimens: results of the Mexican approach. Int J Hematol 2002;76(Suppl 1):376-379.
8. Gómez-Almaguer D, Ruiz-Argüelles GJ, Tarín-Arzaga LC, et al. Reduced-intensity stem cell transplantation in children and adolescents: the Mexican experience. Biol Blood Marrow Transpl 2003;9:157-161.
9. Boeckh MJ, Ljungman P. Cytomegalovirus infection after BMT. In: Bowden RA, Ljungman P, Paya CV, editors. Transplant infections. Philadelphia: Lippincott-Raven; 1998. p 215-228.
10. Giralt S. Complications of non-myeloablative stem cell transplantation. In: Giralt S, Slavin S, editors. New frontiers in cancer therapy: non-myeloablative stem cell transplantation. Abingdon, U.K.: Darwin Scientific Publishing; 2000. p 149-148.
11. Storek J, Dawson MA, Storer B, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001;97:3380-3389.
12. th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Ontario, Canada. Abstract 779.
13. Ruiz-Argüelles GJ. Gómez-Almaguer D, López-Martinez B, Ponce-de-León S, Cantú-Rodríguez OG, Jaime-Pérez JC. No cytomegalovirus-related deaths after non-ablative stem cell allografts. Hematology 2002;7:95-99.
14. Bainton RD, Byrne JL, Davy BJ, Russel NH. CMV infection following nonmyeloablative allogeneic stem cell transplantation using Campath. Blood 2002;100:3843-3844.
15. Chakrabarti S. Increased CMV infection following nonmyeloablative allogeneic stem cell transplantation: a search for the guilty. Blood 2003;101:2071-2072.
16. Ruiz-Argüelles A. Flow cytometry in the clinical laboratory. Principles, applications and problems. Ann Biol Clin 1992;50:735-743.
17. Ruiz-Argüelles A, Orfao A. Caracterización y evaluación de células totipotenciales en sangre periférica y médula ósea. In: Ruiz-Argüelles GJ, San-Miguel JF, editors. Actualización en leucemias. Mexico City: Editorial Médica Panamericana; 1996. p 79-82.
18. Fiore M, Mitchell J, Doan T, Nelson R, Winter G, Grandone C. The Abbot IMX automated benchtop immunochemistry analyzer system. Clin Chem 1988;34:1726-1732.
19. Velzing J, Rothbarth PH, Kroes ACM, Wuint WGV. Detection of cytomegalovirus mRNA and DNA encoding the immediate early gene in peripheral blood leukocytes from immunocompromised patients. J Med Virol 1994;42:164-169.
20. Nelson PN, Rawal BK, Boriskin YS, et al. A polymerase chain reaction to detect a sliced late transcript of human cytomegalovirus in the blood of bone marrow transplant recipients. J Virol Methods 1996;56:139-148.
21. Ho M. Epidemiology of CMV infections. Rev Infect Dis 1990;12(Suppl 7):S701-710.
22. Wingard JR, Chen DY, Burns WH, et al. CMV infection after autologous bone marrow transplantation with comparison to infection after allogeneic BMT. Blood 1988;71:1432-1437.
23. D'Agaro P, Andolina M, Burgnich P, et al. Surveillance of CMV infection in bone marrow transplant in Trieste: seven years' experience. Haematologica 2000;85(Suppl):54-57.
24. Millere W, Flynn P, McCullough J, et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-bost disease. Blood 1986;67:1162-1167.
25. Maltezou H, Whimbey E, Abi-Said D, Przepiorka D, Champlin R, Goodrich J. Cytomegalovirus disease in adult marrow transplant recipients receiving ganciclovir prophylaxis: a retrospective study. Bone Marrow Transplant 1999;24:665-669.
26. Mohty M, Faucher C, Vey N, et al. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. Bone Marrow Transplant 2000;26:251-255.
27. Redy V, Pollock BH, Sharda S, et al. GVHD and CMV antigenemia after allogeneic peripheral blood stem cell transplantation: comparison between myeloablative and non-myeloablative (mini) conditioning regimens. Blood 2000;96(Suppl 1):191a.
28. Junghans C, Boeckh M, Carter R, et al. Incidence of herpesvirus infections following nonmyeloablative allogencie stem cell transplantation. Blood 2000;96(Suppl 1):188a.
29. Reynoso EE, Sánchez-Cruz P, Verástegui E, Sobrevilla PJ, García F, Mohar A. Prevalence of cytomegalovirus infection among patients and blood donors at the Instituto Nacional de Cancerología, México. Blood 1991;78(Suppl 1);354a.
30. Ruiz-Argüelles GJ. Gómez-Almaguer D. The Mexican approach to conduct non-myeloablative stem cell transplantation should not be overlooked. Int J Hematol 2003;77:526-527.